Baricitinib: A Review in Moderate to Severe Atopic Dermatitis

Baricitinib (Olumiant(®)) is an oral small molecule inhibitor of Janus kinase (JAK)1 and JAK2, which have been implicated in the pathogenesis of atopic dermatitis (AD). In phase III studies in adults with moderate to severe AD who were inadequately controlled with topical corticosteroids (TCS) or sy...

Descripción completa

Detalles Bibliográficos
Autor principal: Hoy, Sheridan M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9061224/
https://www.ncbi.nlm.nih.gov/pubmed/35503162
http://dx.doi.org/10.1007/s40257-022-00684-1